e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Biomarkers for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
EGFR
and
hTERT
mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications
R. Cherneva, O. Georgiev, D. Petrova, B. Rukova, D. Toncheva (Toncheva, Bulgaria)
Source:
Annual Congress 2010 - Biomarkers for lung cancer
Session:
Biomarkers for lung cancer
Session type:
Thematic Poster Session
Number:
3235
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Cherneva, O. Georgiev, D. Petrova, B. Rukova, D. Toncheva (Toncheva, Bulgaria).
EGFR
and
hTERT
mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications. Eur Respir J 2010; 36: Suppl. 54, 3235
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
EGF-receptor mutation in non-small cell lung cancer – Experiences by routine molecular testing in a German lung cancer centre
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
TTF-1 in advanced SCLC – Diagnostic and prognostic relevance
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
HER2/
Neu
overexpression as independent negative prognostic factor for non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Octogenarians with non-small cell lung carcinoma – Advanced disease
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Survival outcomes in advance non-small cell lung cancer – A developing country scenario
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011
Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
FEV
1
is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011
Lung function and quality of life after surgical treatment of non-small cell lung cancer – preliminary results
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Is
MIF -173G/C
polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Source: Eur Respir J 2009; 33: 127-133
Year: 2009
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept